Products
Inezetamab Biosimilar Bispecific Antibody (CD40 × Mesothelin) for Research
Cat No.: GMP-Bios-INN-1237
Anti-CD40 therapeutic antibody (Pre-made Inezetamab biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Inezetamab (development code AMG 994) is a bispecific antibody targeting mesothelin (MSLN). It is developed by Amgen for solid tumors. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1237-1mg | 1mg | |
| GMP-Bios-INN-1237-10mg | 10mg | |
| GMP-Bios-INN-1237-100mg | 100mg | |
| GMP-Bios-INN-1237-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Inezetamab biosimilar, Bispecific Mixed mAb and scFv, Anti-CD40;MSLN Antibody: Anti-CD40/Tumor necrosis factor receptor superfamily member 5/B-cell surface antigen CD40/Bp50 therapeutic antibody |
| INN Name | Inezetamab |
| Target | CD40;MSLN |
| Format | Bispecific Mixed mAb and scFv |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;na |
| VD LC | Lambda;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Amgen |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
